MEDICAL NEWS SITES

Targeted Oncology

EGFR+ Lung Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways


Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.


Read more

8532ed7d4f07250ff3bfd22d735562a9e201e813-200x200.jpg

OncLive

Osimertinib Improves CNS Disease-Free Survival in Early EGFRm NSCLC


Osimertinib (Tagrisso) reduced the risk for central nervous system (CNS) death or progression by 82% in patients with early-stage EGFR mutated non–small cell lung cancer (NSCLC) following complete tumor resection, according to findings presented at the European Society of Medical Oncology (EMSO) Virtual Congress 2020, held September 17, 2020 to September 21, 2020. Masahiro Tsuboi, MD, PhD, a principal investigator for the trial, said that, based on these data, adjuvant osimertinib would be an effective and practice-changing treatment in this setting. Tsuboi, director of the Department of Thoracic Surgery and Oncology for Japan’s National Cancer Center Hospital East, added that treatment with osimertinib was associated with fewer locoregio...


Read more

ad0ee113b9771c567b6e6e1ca26ec917cd6b5b60-7000x5430.jpg

Cancer Network

Osimertinib Found to Reduce Risk of CNS Death or Progression in Early EGFRm NSCLC


According to study findings presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, held September 17 to September 21, 2020, osimertinib (Tagrisso) reduced the risk for central nervous system (CNS) death or progression by 82% in patients with early-stage EGFR mutated non-small cell lung cancer (NSCLC) following complete tumor resection. Based on these data, Masahiro Tsuboi, MD, PhD, a principle investigator for the trial, said that adjuvant osimertinib would be an effective and practice-changing treatment in this setting. Tsuboi, director of the Department of Thoracic Surgery and Oncology for Japan’s National Cancer Center Hospital East, added that treatment with osimertinib was associated with fewer locoregion...


Read more

d7900c39290ab622077c004f779d234e122d0b1b-480x270.png

Targeted Oncology

Adding Bevacizumab to Osimertinib Failed to Improve PFS in EGFR T790M+ Lung Cancer


Osimertinib (Tagrisso) in combination with bevacizumab (Avastin) did not lead to a prolonged progression-free survival (PFS) compared with osimertinib alone as treatment of patients with advanced adenocarcinoma harboring EGFR T790M, according to findings presented by Yukihiro Toi, MD, during the 2020 ESMO Virtual Congress.1 Toi, from the West Japan Oncology Group 8715L, reported that median PFS in the combination arm was 9.4 months versus 13.5 months for the monotherapy arm (HR, 1.44; 95% CI, 1.00-2.08; P= .20).


Read more

OncLive

Lung Cancer | OncLive


Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.


Read more

a3e386166129f64466717247bba4195ffc345b87-200x200.jpg

OncLive

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC


Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival (OS) and progression-free survival (PFS) versus platinum-doublet chemotherapy as first-line treatment in patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on at least 50% of their tumor cells, according to findings from the second preplanned interim analysis of the phase 3 EMPOWER-Lung 1 trial that were presented during the 2020 ESMO Virtual Congress. At a median follow-up of approximately 10 months in the PD-L1 ≥50% intention-to-treat (ITT) population, the median OS was not reached (95% CI, 17.9–not estimable [NE]) in the cemiplimab arm versus 14.2 months (95% CI, 11.2-17.5) in the chemotherapy arm (HR, 0.57; 95% CI, 0....


Read more

BioSpace

First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)


Sept. 21, 2020 12:25 UTC KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced five-year survival results from the pivotal Phase 3 KEYNOTE-024 trial, which demonstrated a sustained, long-term survival benefit and durable responses with KEYTRUDA, Merck’s anti-PD-1 therapy, versus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (tumor proportion score [TPS] ≥50%) with no EGFR or ALK genomic tumor aberrations.


Read more

BioSpace

Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%


TARRYTOWN, N.Y. and PARIS, Sept. 21, 2020 /PRNewswire/ --  - In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy - In a prespecified analysis of patients with confirmed PD-L1 expression of ≥50%, Libtayo reduced risk of death by 43% Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN) and Sanofi today announced the presentation of positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.


Read more

apple-touch-icon.png

MedWireNews

Postoperative RT ‘not recommended’ for resected advanced NSCLC


medwireNews: Patients with completely resected stage IIIA N2 non-small-cell lung cancer (NSCLC) do not benefit from postoperative radiotherapy (PORT), show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020. In a statement to the press, presenting author Cécile Le Pechoux (Institut Gustave Roussy, Paris, France) said: “PORT cannot be recommended for all patients with stage II and III NSCLC with mediastinal nodal involvement.” However, she noted that PORT could be useful for some patients “because it does decrease the rate of mediastinal relapse by 50% [but this] must be put into balance with the risk of over-added cardio-pulmonary toxicity.” The study included 501 patients (median age 61 years, 66% men) wh...


Read more

BioSpace

Dr. Keith Nemec of Total Health Institute discusses cancer stem cells for cancer treatmentDr. Keith Nemec is the Director of Total Health Institute


Carol Springs, IL, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Keith describes cancer stem cells as the key drivers to the growth and spread of cancer. He adds that getting these stem cells to dedifferentiate normally would heal the disease.  Keith states that for the process to be reversed and cancer cells to start dedifferentiating normally, the internal environment in the body has to be right. He adds that the right internal environment is determined by physical, mental, and emotional factors. To quote him, “Only when an environment that produces health is achieved will the cancer cells revert to normal healthy cells.” For simplicity, Dr.


Read more

dt_200921_covid_coronavirus_oncology_800x450.jpg

MedScape

Survey Quantifies COVID-19's Impact on Oncology


Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. An international survey provides new insights into how COVID-19 has affected, and may continue to affect, the field of oncology. The survey showed that "COVID-19 has had a major impact on the organization of patient care, on the well-being of caregivers, on continued medical education, and on clinical trial activities in oncology," stated Guy Jerusalem, MD, PhD, of Centre Hospitalier Universitaire de Liège (Belgium). Dr.


Read more

88726.jpg

MedPageToday

A Sinister Etiology for Shoulder Pain


A 60-year-old man presents to an emergency department in Dammam, Saudi Arabia, with ongoing burning pain in his right shoulder. He notes that the pain began about 6 months earlier, has gradually worsened, and has not responded to pain killers. He says he experiences the pain throughout the day, and rates it as 7 out of 10 on the severity scale. He explains that the pain has started to interfere with his sleep and quality of life, that it is non-radiating, and that he has no weakness or sensory changes. The patient notes that his work involves manual labor, but that he has not had an injury that might account for the pain.


Read more

OncLive

Author | Caroline Seymour | OncLive


Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.


Read more

59cbd5264882fda2d820843b2ddff50369233b2a-225x225.jpg

OncLive

Cabozantinib Combo Induces Clinical Activity in Advanced ccRCC


Treatment with cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC), according to results from the phase 1b COSMIC-021 study presented at the virtual 2020 ESMO Congress. Objective response rates (ORRs) per investigator by RECIST v1.1 were 53% (80% CI, 41-65) in the 40-mg cohort and 58% (80% CI, 46-70) in the 60-mg cohort. Complete responses were observed in 1 patient in the 40-mg group and 4 patients in the 60-mg group; while 17 partial responses in each cohort were also seen.


Read more

d7900c39290ab622077c004f779d234e122d0b1b-480x270.png

Targeted Oncology

Cabozantinib Doublet Achieves Early Clinical Activity in Advanced ccRCC


Patients with advanced clear cell renal cell carcinoma (ccRCC) treated with cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) in the phase 1b COSMIC-021 study, had promising clinical activity, according to results from the study presented during the 2020 European Society of Medical Oncology (ESMO) Virtual Congress. Objective response rates (ORRs) per investigator by RECIST v1.1 were 53% (80% CI, 41-65) in the 40-mg cohort and 58% (80% CI, 46-70) in the 60-mg cohort. Complete responses were observed in 1 patient in the 40-mg group and 4 patients in the 60-mg group; while 17 partial responses in each cohort were also seen.


Read more

BioSpace

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer


“Esophageal cancer is an aggressive disease that is associated with very poor survival, and there is an urgent need for advances for newly diagnosed, previously untreated patients,” said Dr. Ken Kato, chief, department of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. “In KEYNOTE-590, with a 27% reduction in the risk of death, the results show KEYTRUDA has the potential to change the current treatment paradigm for the first-line treatment of patients with locally advanced and unresectable or metastatic esophageal or esophagogastric junction cancer.


Read more

acd56bfc304dc2a2652410d6cfe89f64078d7c10-1000x667.jpg

Cancer Network

Cabozantinib Plus Atezolizumab Shows Promising Clinical Activity in Advanced Clear Cell Renal Cell Carcinoma


Treatment with cabozantinib (Cabometyx), at a 40 mg or 60 mg dose, in combination with atezolizumab (Tecentriq) induced promising clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC), according to results from the phase 1b COSMIC-021 study presented at the 2020 ESMO Virtual Congress. Objective response rates (ORRs) per investigator by RECIST v1.1 were 53% (80% CI, 41-65) in the 40-mg cohort and 58% (80% CI, 46-70) in the 60-mg cohort. Complete responses were observed in 1 patient in the 40-mg group and 4 patients in the 60-mg group; while 17 partial responses in each cohort were also seen.


Read more

Cancer Network

All News | Cancer Network


Osimertinib Found to Reduce Risk of CNS Death or Progression in Early EGFRm NSCLC Based on these data, researchers indicated that adjuvant osimertinib would be an effective and practice-changing treatment in this setting.


Read more

biocept_inc_Logo.jpg

BioSpace

Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy


SAN DIEGO, Sept. 21, 2020 /PRNewswire/ -- Biocept, Inc.. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Highmark, America's fourth largest Blue Cross Blue Shield affiliate, has made a positive coverage determination that Biocept's Target Selector liquid biopsy assay has been accepted for medical coverage for use in the diagnosis and treatment of patients with non-small cell lung cancer (NSCLC).  The coverage determination follows two years of evaluation performed by the Allegheny Health Network Cancer Institute of Biocept's liquid biopsy assay to more rapidly assess the molecular stat...


Read more

BioSpace

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte


ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc.,  (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $15 million milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab (MGA012), an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA00012).


Read more

;w=625;h=350

BioSpace

ESMO News: AstraZeneca, Merck, Janssen, Amgen and More


The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates. Here’s a roundup of some of the big stories that came out of the meeting. AstraZeneca and Merck announced final results from the Phase III PROfound trial demonstrating Lynparza showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) patients who have BRCA1/2 or ATM gene mutations.


Read more

;w=625;h=350

BioSpace

Clinical Catch-Up: September 14-18


It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. Here’s a look. COVID-19-related Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19. The study enrolled mild-to-moderate COVID-19 patients who had recently been diagnosed in the outpatient setting and received either placebo, 700 mg, 2800 mg and 7000 mg of the antibody. The primary endpoint of the trial is change from baseline in viral load at day 11.


Read more

BioSpace

Clinical Trials News (Phase III) | BioSpace


Get news straight to your inbox by signing up for our free eNewsletters It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. The overall survival benefit of the drug was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer. Ad Hoc Analysis of ARAMIS Showed a High Percentage (97.2%) of Men with Non-Metastatic Castration-Resistant Prostate Cancer Received Full, Planned Dosing of NUBEQA® (darolutamide) A new ad hoc analysis from the Phase III ARAMIS trial showed 97.2% of men with non-metastatic castration-resistant prostate cance...


Read more

dt_200918_target_bullseye_800x450.jpg

MedScape

Sotorasib Is a 'Triumph of Drug Discovery' in Cancer


KRAS, one of the most frequently mutated oncogenes in human cancer, has long been thought to be "undruggable," but early results from a clinical trial of the experimental KRAS-inhibitor sotorasib (Amgen) suggest that at least one KRAS mutation common in non-small cell lung cancers (NSCLC) has a soft underbelly. In the phase 1 CodeBreaK 100 trial, sotorasib, an investigational first-in-class inhibitor of the KRAS p.G12C mutation, showed encouraging activity against advanced NSCLC and other solid tumors. Among patients with NSCLC, 19 (32.2%) of 59 had a confirmed objective response to sotorasib monotherapy, and 52 (88.1%) had disease control, reported David S.


Read more

NEWS SITES

200922091315-taipei-life-during-covid-2-super-tease.jpg

CNN

Taiwan offers a glimpse into a post Covid-19 world


Taipei, Taiwan (CNN) New arrivals to Taiwan might be forgiven for thinking they've stepped back in time. On the streets of the island's capital, Taipei, pedestrians appear more concerned with staying out of the hot midday sun than maintaining any semblance of social distancing. Large lines stretch along the sidewalks, as people cram into popular lunchtime eateries. And in nearby parks, large groups of young people exercise and practice dance routines. In fact, there are few if any visible signs that this is 2020 and the world is in the grip of a raging pandemic. As the global number of confirmed Covid-19 cases surpasses 30 million, residents of Taipei seem relaxed in the knowledge there has been only one suspected case linked to local tr...


Read more

2500.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-align=bottom%2Cleft&overlay-width=100p&overlay-base64=L2ltZy9zdGF0aWMvb3ZlcmxheXMvdGctZGVmYXVsdC5wbmc&enable=upscale&s=44b51e729c01cdc9ea67d341531c584f

The Guardian

Revealed: asbestos-contaminated waste found in landscaping material at new Sydney housing estate site


Asbestos-contaminated waste has been dumped at one of Sydney’s newest building projects after having been passed off as safe landscaping, according to whistleblowers. Guardian Australia has spoken to multiple people who have revealed that contaminated soil was processed into a product known as “turf underlay” then taken to at least one new suburb, Oran Park, which will eventually be home to 25,000 households near Camden on Sydney’s south-west fringe. The whistleblowers have provided pictures and recorded evidence of the waste being processed and transported to at least one site. One council waste inspector told the Guardian he had inspected a site that he suspected contained dumped asbestos.


Read more

4350.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-align=bottom%2Cleft&overlay-width=100p&overlay-base64=L2ltZy9zdGF0aWMvb3ZlcmxheXMvdGctZGVmYXVsdC5wbmc&enable=upscale&s=5c6ce0de5845871d50b2bbd8567a63b4

The Guardian

TV tonight: battenberg in a bubble as Bake Off returns


Now no longer just a baking tent, but also a social bubble, Bake Off has weathered the storm of the pandemic to return for a new series of oven-based delights and disasters. Paul Hollywood and Prue Leith return as our steadfast expert taste testers, while presenting comes from the veteran Noel Fielding and newbie Matt Lucas. It is cake week for the 12 amateur bakers as Prue and Paul request a geometric battenberg, while a fruit sponge is in store for the technical. There is one bubble and only one champion to be crowned.


Read more

JOURNALS

Cancer Discovery

Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade


Abstract Real-world evidence (RWE) - conclusions derived from analysis of patients not treated in clinical trials - is increasingly recognized as an opportunity for discovery, to reduce disparities, and to contribute to regulatory approval. Maximal value of RWE may be facilitated through machine learning techniques to integrate and interrogate large and otherwise underutilized data sets. In cancer research, an ongoing challenge for RWE is the lack of reliable, reproducible, scalable assessment of treatment-specific outcomes.


Read more

41416_2020_1088_Fig1_HTML.png

Nature

CB11, a novel purine-based PPARɣ ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells


Peroxisome proliferator-activated receptor γ (PPARγ) agonists frequently induce cell death in human non-small-cell lung cancer (NSCLC) cells. However, majority of NSCLC patients acquire resistance after cancer therapy, and it is still unclear. In this study we investigated the apoptotic mechanism and the anti-cancer effects of a novel purine-based PPARγ agonist, CB11 on human NSCLC cells. CB11 mediates PPARγ-dependent cell death, reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP) collapse, cell cycle arrest, lactate dehydrogenase (LDH) cytotoxicity, and caspase-3 activity in human NSCLC cells. CB11 causes cell death via ROS-mediated ATM-p53-GADD45α signalling in human NSCLC cells, and diphenyleneiodonium (DP...


Read more

fx1.jpg

Cell

microRNA-130b-3p Contained in Mesenchymal Stem Cell-Derived Extracellular Vesicles Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis


This study aimed to explore the molecular mechanism by which mesenchymal stem cells (MSCs) mediate lung cancer progression. Extracellular vesicles (EVs) were isolated from transfected or untransfected MSCs, and were used to treat lung cancer with/without inhibitor, mimic, overexpression plasmid or shRNAs. CCK-8 assay, colony formation, transwell assay and flow cytometry were carried out to determine biological functioning of lung cancer cells. Furthermore, FOXO3, Keap1, NFE2L2 and TXNRD1 expression was determined by RT-qPCR and Western blot analysis.


Read more

favicon.ico

Dove Press

Knockdown of PVT1 Suppresses Colorectal Cancer Progression by Regulati | CMAR


Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide and has grown rapidly in China in recent years.1 Despite the development in systemic therapy and liver-directed treatments, about 86% of patients with advanced disease still die within 5 years after diagnosed.2 Therefore, a better understanding on molecular mechanisms and genetic alterations underlying CRC to find out the novel therapeutic strategies in treating CRC is of great importance. Long non-coding RNAs (LncRNAs) are a class of non-coding ribonucleic acids (RNAs), which are longer than 200 nts in size.


Read more

favicon.ico

Dove Press

LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarc


Junbin Wang1,2 ,* Jin Gao1 ,* Qinnan Chen,1 Weiyan Zou,3 Fen Yang,4 Chenchen Wei,1 Zhaoxia Wang1 1Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, People’s Republic of China; 2Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, People’s Republic of China; 3Department of Histology and Embryology, Bengbu Medical College, Bengbu 233030, People’s Republic of China; 4Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, People’s Republic of China *These authors contributed equally to this work Correspondence: Zhaoxia Wang; Chenchen Wei Department of Oncology, The Sec...


Read more

favicon.ico

Dove Press

Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approa


Patients who have just been diagnosed with the type of non-small-cell lung cancer (NSCLC) known as squamous NSCLC usually receive chemotherapy or an immune checkpoint inhibitor (for example, pembrolizumab). Immune checkpoint inhibitors may be given either alone or in combination. For patients who have stopped responding to immune checkpoint inhibitors and chemotherapy, alternative treatments are limited and needed. One possible option is afatinib, an orally administered drug that specifically targets a receptor in the cell membrane of the tumor cell, called the epidermal growth factor receptor (EGFR).


Read more

favicon.ico

Dove Press

Diagnosis Value of Combined Detection of Serum SF, CEA and CRP in Non- | CMAR


Jing Zhou, Xin Diao, Shengyu Wang, Yang Yao Department of Respiratory and Critical Care, The First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi 710077, People’s Republic of China Correspondence: Yang Yao Department of Respiratory and Critical Care, The First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi 710077, People’s Republic of China Tel +86 15902939063 Email The aim of this study was to evaluate the clinical diagnostic value of combined detection of serum ferritin (SF), carcino-embryonic antigen (CEA) and C-reactive protein (CRP) in non-small cell lung cancer (NSCLC). Methods: The study included 70 patients with NSCLC, 50 patients with benign lung disease and 50 healthy subjects.


Read more

favicon.ico

Dove Press

Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small C


Mei Jiang1 *,* Qi Chen1 *,* Xiaoting Zhao,1 Yu Teng,1 Chenghong Yin,2 Wentao Yue1 1Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, People’s Republic of China; 2Departments of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, People’s Republic of China *These authors contributed equally to this work Correspondence: Wentao Yue Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, No.


Read more

13550_2020_695_Fig8_HTML.png?as=webp

Springer

Convolutional neural networks for improving image quality with noisy PET data


Abstract PET is a relatively noisy process compared to other imaging modalities, and sparsity of acquisition data leads to noise in the images. Recent work has focused on machine learning techniques to improve PET images, and this study investigates a deep learning approach to improve the quality of reconstructed image volumes through denoising by a 3D convolution neural network. Potential improvements were evaluated within a clinical context by physician performance in a reading task. A wide range of controlled noise levels was emulated from a set of chest PET data in patients with lung cancer, and a convolutional neural network was trained to denoise the reconstructed images using the full-count reconstructions as the ground truth.


Read more

41568_2020_299_Fig1_HTML.png

Nature

The evolving translational potential of small extracellular vesicles in cancer


1.Galdiero, M. R., Marone, G. Mantovani, A. Cancer inflammation and cytokines. Cold Spring Harb. Perspect. Biol. (2018). Article  PubMed  PubMed Central  Google Scholar  2.Thomas, S. K., Lee, J. Beatty, G. L. Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. EBioMedicine (2020). Article  PubMed  PubMed Central  Google Scholar  3.Kalluri, R. LeBleu, V. S.


Read more

CONFERENCES

European Society for Medical Oncology

Management of NSCLC After Progression on EGFR TKIs Remains a Challenge


Despite several strategies to overcome resistance to EGFR tyrosine kinase inhibitors (TKIs) being investigated in an effort to improve outcomes in patients with non-small-cell lung cancer (NSCLC) after progression, diverse results from some studies have been presented at ESMO Virtual Congress 2020. “Preclinical and clinical evidence suggests that EGFR TKIs may work synergistically with VEGF inhibitors,” says Prof. Martin Reck, LungenClinic Grosshansdorf, Grosshandorf, Germany, commenting on one such strategy, “and there have been some positive data when first-generation EGFR TKIs have been combined with bevacizumab in untreated patients.” Here, disappointing data have been reported from a phase II study for the third-generation EGFR TKI, os...


Read more

European Society for Medical Oncology

ESMO Virtual Congress 2020: Press & Media


Media registration ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events. Accredited journalists will have access to the ESMO official press conferences (as per timeline area, the virtual exhibition area, industry satellite symposia, and the congress webcasts. The media accreditation process is closed, please refer to the ESMO Press Office (media@esmo.org) for any question. ESMO Press Programme  The following abstracts are currently included in the ESMO Press Programme and will be ac...


Read more

European Society for Medical Oncology

Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to Improve Patient Outcome Following Immune Checkpoint Inhibitor Therapy


Patients receiving immune checkpoint inhibitor (ICI) treatment who developed a rheumatic immune-related adverse event (irAE) displayed symptoms that resembled classical rheumatic and musculoskeletal diseases (RMDs), but seldom fulfilled their classification criteria mainly due to dissimilar laboratory characteristics. These and other findings were presented by Dr Karolina Benesova of the Department of Medicine V, Haematology, Oncology and Rheumatology, University Hospital in Heidelberg, Germany at the ESMO Virtual Congress 2020. Dr Benesova discussed the occurrence and characteristics of rheumatic irAEs which have been associated with better tumour response following treatment with ICIs.


Read more

FINANCE SITES

4709149811c2c9913522ccc4231e9335

Yahoo Finance

Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%


TARRYTOWN, N.Y. and PARIS, Sept. 21, 2020 /PRNewswire/ --  - In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy - In a prespecified analysis of patients with confirmed PD-L1 expression of ≥50%, Libtayo reduced risk of death by 43% Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.


Read more

31ee40c6a1ae6e3a26e0b45e753447e7

Yahoo Finance

First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)


Results From KEYNOTE-024 Represent Longest Follow-Up of an Immunotherapy in a Randomized Phase 3 Study for the First-Line Treatment of Lung Cancer Duration of Response With KEYTRUDA As Monotherapy (29.1 Months) Was Nearly Five Times Longer Than Chemotherapy (6.3 Months) Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced five-year survival results from the pivotal Phase 3 KEYNOTE-024 trial, which demonstrated a sustained, long-term survival benefit and durable responses with KEYTRUDA, Merck’s anti-PD-1 therapy, versus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (tumor proportion score [TPS] ≥50%) with no EGFR or ALK genomic t...


Read more

130a87763de025227bdfa1fd6a3650c6

Yahoo Finance

Philips paves the way for faster lung cancer diagnosis and treatment with advanced 3D imaging and navigation platform


September 21, 2020 Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced Azurion Lung Edition, an advanced 3D imaging and navigation platform to accelerate the diagnosis and treatment of lung cancer. The suite combines CT-like 3D images acquired at the tableside (Cone Beam CT) with live X-ray guidance and advanced tools to support image-guided lung procedures.


Read more

https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F5f68c44bb86e8ea71885c4de%2F0x0.jpg

Forbes

Cancer Disparities Continue To Impact Minority Populations In The United States


Black people with cancer still have a significantly higher chance of dying from their disease than ... [+] white people. What is being done to tackle these disparities? getty A new report from the American Association for Cancer Research has identified several health disparities which disproportionately effect certain groups of people in the U.S. with cancer. The report looks at several factors which influence cancer outcomes such as diagnoses, access to clinical trials and treatments and quality of life after cancer treatment.


Read more

biotech_min.jpeg

Seeking Alpha

PMV Pharmaceuticals Seeks $125 Million To Enter Trials (Pending:PMVP)


The company is still an ultra-early stage, so the IPO may be more suited to institutional investors. PMVP just received approval to enter Phase 1 trials for its lead candidate. The firm is developing treatments for various cancers. PMV Pharmaceuticals has filed proposed terms for its U.S. IPO plan. PMV Pharmaceuticals (PMVP) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing tumor agnostic gene therapies for a wide range of cancers. While PMVP has recently received approval to enter Phase 1 trials for its lead candidate, the firm is still at a preclinical stage of development and thus is likely more suited to long-term hold institutional investors. Cranbur...


Read more

og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png

Seeking Alpha

MacroGenics MGD019 shows anti-tumor activity in advanced solid tumors (NASDAQ:MGNX)


MacroGenics (MGNX ) announces clinical data from the dose escalation portion of a Phase 1 clinical trial of MGD019. The data were presented at the ESMO Virtual Congress 2020. MGD019, a bispecific PD-1 × CTLA-4 DART molecule, was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells. Forty-three patients were enrolled within a dose range of 0.03 – 10.0 mg/kg in patients with different types of solid tumors.


Read more

og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png

Seeking Alpha

Blueprint Medicines says durable clinical benefits observed for Gavreto in thyroid cancer (NASDAQ:BPMC)


Blueprint Medicines (BPMC ) has announced results from the ongoing ARROW (Phase 1/2) trial for GAVRETO (pralsetinib) in patients with advanced RET-mutant medullary thyroid cancer (MTC). The data were presented at the European Society for Medical Oncology Virtual Congress. In 53 previously treated patients (with cabozantinib or vandetanib), GAVRETO demonstrated overall response rate (ORR) was 60%, and the disease control rate (DCR) of 96% Median duration of response was not reached, with 94% of responders remaining on treatment.


Read more

og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png

Seeking Alpha

MacroGenics announces development milestone achieved in retifanlimab collaboration with Incyte (NASDAQ:MGNX)


MacroGenics (NASDAQ:MGNX) announced a $15M milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab (MGA012). The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and safety of retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous non-small cell lung cancer. Under the collaboration agreement with Incyte, the company is eligible to receive up to a total of $390M in potential remaining development and regulatory milestones and up to $330M in potential commercial milestones.


Read more

og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png

Seeking Alpha

Amgen's sotorasib shows encouraging clinical benefit in KRAS G12C-mutant tumors (NASDAQ:AMGN)


Amgen (NASDAQ:AMGN) announces updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors. Data from 59 patients with advanced non-small cell lung cancer (NSCLC) were reported at ESMO 2020 and in the New England Journal of Medicine. Sotorasib demonstrated confirmed objective response rate (ORR) and disease control rates (DCR) of 35.3% and 91.2%, respectively, in 34 heavily pretreated patients (median of two prior lines of therapy) with NSCLC who were treated with the 960 mg daily dose (data cutoff of June 1, 2020). Anticancer activity was seen across all dose levels, with a confirmed ORR of 32.2% and DCR of 88.1%, and ...


Read more

og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png

Seeking Alpha

Merck announces encouraging data on three pipeline candidates at ESMO (NYSE:MRK)


Merck (NYSE:MRK) announces data presentations at ESMO on pipeline candidates vibostolimab (MK-7684), MK-4830 and MK-6482. Phase 1 study evaluating anti-TIGIT therapy vibostolimab, combined with Keytruda (pembrolizumab), in patients with non-small cell lung cancer (NSCLC) most of whom had received more than one prior line of therapy but none a PD-1/L1 inhibitor, showed a manageable safety profile and a 29% overall response rate (ORR). Median progression-free survival (PFS) was 5.4 months. Median duration of response (DOR) was not reached.


Read more

yahoo_default_logo-1200x1200.png

Yahoo Finance

Basilea reports data from poster presentations at ESMO Virtual Congress 2020


Gene expression data may explain differences in clinical adverse event profiles of FGFR inhibitors Antitumor activity of derazantinib in preclinical cancer models with FGFR aberrations supports planned gastric cancer study Full results from the completed phase 1 study in patients with brain cancer underscores the potential for lisavanbulin to be developed in a targeted patient population using end-binding protein 1 (EB1) as a patient selection criterion Basel, Switzerland, September 22, 2020 Basilea Pharmaceutica Ltd.


Read more

1d6a74773d9237d6fa2b036160936777

Yahoo Finance

Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy


Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs SAN DIEGO, Sept. 21, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Highmark, America's fourth largest Blue Cross Blue Shield affiliate, has made a positive coverage determination that Biocept's Target Selector liquid biopsy assay has been accepted for medical coverage for use in the diagnosis and treatment of patients with non-small cell lung cancer (NSCLC).  The coverage determination follows two...


Read more

PHARMA SITES

CT?id=bwnews&sty=20200921005172r1&sid=acqr8&distro=nx&lang=en

Merck

First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ≥50%)


Results From KEYNOTE-024 Represent Longest Follow-Up of an Immunotherapy in a Randomized Phase 3 Study for the First-Line Treatment of Lung Cancer Duration of Response With KEYTRUDA As Monotherapy (29.1 Months) Was Nearly Five Times Longer Than Chemotherapy (6.3 Months) KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced five-year survival results from the pivotal Phase 3 KEYNOTE-024 trial, which demonstrated a sustained, long-term survival benefit and durable responses with KEYTRUDA, Merck’s anti-PD-1 therapy, versus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (tumor proportion score [TP...


Read more

CT?id=bwnews&sty=20200921005599r1&sid=acqr8&distro=nx&lang=en

Merck

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer


KEYTRUDA Plus Chemotherapy Demonstrated Superior Overall Survival and Progression-Free Survival Versus Chemotherapy in These Patients Regardless of PD-L1 Expression Status and Tumor Histology Results From Pivotal KEYNOTE-590 Trial Presented for the First Time at ESMO Virtual Congress 2020 During Presidential Symposium KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal jun...


Read more

SOCIAL MEDIA

ProfilePicture.png

Twitter

Navneet Singh ESMO20, lungcancer, NSCLC, LCSM: 21/09/2020 13:53:05


Yes, 3 takeaways from @DrRoyHerbstYale discussion of KN-24 5 yr OS, EMPOWER (cemiplimab) @barlesi PIONEER study & at @myESMO #ESMO20 - personalise immunotherapy, targeted immunotherapy & public-private partnerships. Goal: attempting to ‘cure’ metastatic #lungcancer #NSCLC ! #LCSM


Read more

ProfilePicture.png

Twitter

Targeted Oncology ESMO20, NSCLC, lcsm: 21/09/2020 14:02:39


“This is the first study with such a short time between one injection of immunotherapy and surgery. It was safe and did not impair surgery.” #ESMO20


Read more

ProfilePicture.png

Twitter

Rhonda Meckstroth ESMO2020, NSCLC: 21/09/2020 15:18:38


#ESMO2020 I/O for NSCLC is a key interest of research! A notable trend within @ALKLungCancer is the RUSH to treat ALL #NSCLC with Immunotherapy prior to comprehensive biomarker testing or receiving the diagnostic results. I/O research is important but we need to test, not guess!


Read more

ProfilePicture.png

Twitter

Oncology Knowledge into Practice NSCLC, ESMO20: 21/09/2020 15:26:11


Following the presentation of Keynote024, as well as EMPOWER-Lung 1 (cemiplimab) and the PIONeeR study (pembrolizumab or atezolizumab), @DrRoyHerbstYale's discussion concluded that immunotherapy could be curative for patients with #NSCLC, but personalisation is key. #ESMO20


Read more

ProfilePicture.png

Twitter

VJ Oncology LCSM, NSCLC, LungCancer, OncoAlert, ESMO20: 21/09/2020 16:19:55


📢VIDEO: Immunotherapy trial updates in NSCLC from ESMO 2020 with @DrRoyHerbstYale @YaleCancer Full interview here: 👉https://t.co/XTGrsDnuir #LCSM #NSCLC #LungCancer @OncoAlert @myESMO #OncoAlert #ESMO20


Read more

ProfilePicture.png

Twitter

Cancer Discovery OnlineFirst, DeepLearning, NSCLC, LungCancer, Immunotherapy: 21/09/2020 18:08:28


Just published #OnlineFirst: #DeepLearning to estimate RECIST in patients with #NSCLC treated with PD-1 blockade. @KCArbourMD @Jia_Luo @JustinGainor @BarzilayRegina @sloan_kettering @MIT_CSAIL @WeillCornell #LungCancer #Immunotherapy https://t.co/MdsHrvaVPl


Read more

ProfilePicture.png

Twitter

Sanofi US ESMO20, immunotherapy, NonSmallCellLungCancer, NSCLC: 21/09/2020 20:00:05


#ESMO20 News: today, we presented investigational #immunotherapy data in first-line advanced #NonSmallCellLungCancer (#NSCLC) alongside @Regeneron. Learn more: https://t.co/1SGtpNKYH5


Read more

ProfilePicture.png

Twitter

ScienceSeeker Feed : 21/09/2020 13:10:01


: AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain


Read more

ProfilePicture.png

Twitter

Helena Linardou ESMO20, OncoAlert: 21/09/2020 20:30:17


Can we cure some merastatic NSCLC patients with immunotherapy? Yes, 1 in 3 with high PDL1!!! Excellent discussion today by Roy Herbst. #ESMO20 #OncoAlert


Read more

ProfilePicture.png

Twitter

OncLive SOSS lcsm: 22/09/2020 02:00:11


.@JSabari, of @nyulangone, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer #lcsm https://t.co/shYKS9EDn2


Read more

ProfilePicture.png

Twitter

OncLive.com lcsm: 22/09/2020 00:00:18


The EMA’s CHMP has recommended the approval of the dual-immunotherapy combination nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the frontline treatment of patients with metastatic NSCLC. #lcsm


Read more

ProfilePicture.png

Twitter

Ray Tobin : 21/09/2020 21:07:12


Immunotherapy and gender differences -meta-analysis of 8 randomized trials, >5,000 NSCLC pts- females derived no PFS benefit, abstract 1041P -study 2, >6,000 pts, suggest PD-L1 expression levels diff. by gender, could be used to guide tx. Abstract 1036P


Read more

ProfilePicture.png

Twitter

🍭🏔 🌈🌎⛹🏻🇺🇸 poziotinib, Rolontis: 21/09/2020 16:17:04


Impressive waterfall plot for #poziotinib in NSCLC with HER2 exon 20 insertions, a clear unmet need, $sppi NDA on the horizon for this niche + #Rolontis BLA PDUFA date upcoming October 24


Read more

ProfilePicture.png

Twitter

Sanofi Immunotherapy, ESMO20: 21/09/2020 13:11:23


#Immunotherapy news from #ESMO20: with @Regeneron, we presented pivotal trial data in first-line advanced Non-Small Cell Lung Cancer (NSCLC). Read more: https://t.co/S8xY2oOQ05


Read more

ProfilePicture.png

Twitter

Jorge Lumbreras Immunotherapy, ESMO20: 21/09/2020 14:09:53


#Immunotherapy news from #ESMO20: with @Regeneron, we presented pivotal trial data in first-line advanced Non-Small Cell Lung Cancer (NSCLC). Read more: https://t.co/P87AmweDTP


Read more

ProfilePicture.png

Twitter

Antonio Passaro, MD PhD ESMO20, LCSM, immunotherapy, lungcancer, immunoterapy: 21/09/2020 13:18:36


👇🏻#ESMO20 #LCSM Amazing conclusion by @DrRoyHerbstYale discussing the role of #immunotherapy in #lungcancer Can we cure metastatic NSCLC with #immunoterapy? ✅ Do we need to personalize immunotherapy? ✅ Looking forward targeted immunotherapy. 🛎The future is now


Read more

ProfilePicture.png

Twitter

Caroline Hopkins ADAURA, ESMO20: 22/09/2020 02:11:20


And on that note, here’s what happened inside the scientific box of #ADAURA at #ESMO20 — but her post should be read first.


Read more